International Organization of MS Nurses
Written by Administrator2
- LETTER TO IOMSN MEMBERS
As we begin 2015, it is my hope that each of you will experience good health and happiness in the months to come. Read more
- JANET PEARCE MULTIPLE SCLEROSIS NURSE EDUCATION PROGRAM 2015
DATE: March 13, 2015 - Friday
LOCATION: The Lighthouse Guild
111 East 59th Street, Between Lexington & Park Avenues
New York, NY 10022
For more details and to register, CLICK HERE.
Download the program flyer.
- THE 7th ANNUAL LINDA MORGANTE MS NURSE LEADERSHIP PROGRAM
May 25-27, 2015 | Indianapolis, IN
This intensive, two-day course on contemporary topics in MS is led by faculty who are thought leaders in MS nursing. The program will be held Monday through Wednesday, May 25-27, 2015, immediately preceding the CMSC Annual Meeting in Indianapolis, Indiana.
For more details and to apply, download the application here.
- MS BLUEPRINT, A UNIQUE NEW TOOL FOR THE MS COMMUNITY, HAS LAUNCHED!
The International Organization of Multiple Sclerosis Nurses (IOMSN) has partnered with Biogen Idec to launch MS Blueprint™, a program to encourage those impacted by MS to set goals, create personalized activity plans called MS Blueprints, and take small steps to attain a more positive life. Learn more
- FDA PERMITS MARKETING OF URINARY PROSTHESIS DEVICE FOR WOMEN
Release Date: October 14, 2014
The U.S. Food and Drug Administration today allowed marketing of the inFlow Intraurethral Valve-Pump, a replaceable urinary prosthesis for use in female adults who cannot contract the muscles necessary to push urine out of the bladder (impaired detrusor contractility or IDC). Learn more
- ACUTE NEUROLOGIC ILLNESS WITH FOCAL LIMB WEAKNESS OF UNKNOWN ETIOLOGY IN CHILDREN
In September, the Centers for Disease Control and Prevention (CDC) issued a Health Advisory to healthcare professionals nationwide to be vigilant for and report cases of neurologic illnesses associated with limb weakness that meet the criteria of its case definition. Learn more.
- PEGYLATED INTERFERON BETA-1A (PLEGRIDY) – CLINICIAN INFORMATION
Generic: Peginterferon Beta-1a
Brand name: Plegridy
US FDA Approved: August 2014
- MS COALITION: The Use of Disease-Modifying Therapies in MS
The member organizations of the Multiple Sclerosis Coalition have collaborated to summarize the current evidence about disease modification in multiple sclerosis (MS) and to provide support for broad access to U.S. Food and Drug Administration (FDA)-approved MS disease-modifying therapies for people.
- Counseling Points: WINTER 2015 Volume 10, Number 3
Advising Patients About Disease-Modifying Therapy Selection and Switching
- MOVING FORWARD:
Adherence to Therapy & the Role of Nursing in MS
- iPointofCare: Managing Patients with MS
This is an innovative evidence-based, clinical resource for MS specialists, providing answers to clinical questions at or near the "point-of-care" - where and when clinicians need it: in the office, in the exam room, on computers, tablets or smart phones. All material is peer-reviewed and faculty-approved.
Release Date: January 25, 2013
Valid Through: January 30, 2015